drugset / Trial / NCT06782139

Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity

NCT06782139

RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this study is to analyze the effects of enavogliflozin on heart function and coronary microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise capacity in these patients.

Timeline

Start
2025-01-20
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Enavogliflozin Small molecule 0.3 mg